Information on new drugs at market entry: Retrospective analysis of health technology assessment reports versus regulatory reports, journal publications, and registry reports

BMJ (Online)

Volumn 350, Issue , 2015, Pages

  Köhler, Michael ^a   Haag, Susanne ^a   Biester, Katharina ^a   Brockhaus, Anne Catharina ^a   McGauran, Natalie ^a   Grouven, Ulrich ^a   Kölsch, Heike ^a   Seay, Ulrike ^a   Hörn, Helmut ^a   Moritz, Gregor ^a   Staeck, Kerstin ^a   Wieseler, Beate ^a  

^a INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ARTICLE; DECISION MAKING; DRUG APPROVAL; DRUG INDUSTRY; DRUG INFORMATION; DRUG MARKETING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE CONCEPTS; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; REGISTER; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; BIOMEDICAL TECHNOLOGY ASSESSMENT; COMPARATIVE STUDY; DRUG CONTROL; GERMANY; MEDICAL TECHNOLOGY; RESEARCH; STANDARDS;

BIOMEDICAL TECHNOLOGY; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG INFORMATION SERVICES; GERMANY; HUMANS; PERIODICALS AS TOPIC; REGISTRIES; RESEARCH REPORT; RETROSPECTIVE STUDIES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84925768154     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h796     Document Type: Article

References (47)

1. European Medicines Agency. Monthly statistics report: Dec 2013. www.ema.europa.eu/docs/en-GB/document-library/Report/2014/01/WC500159715.pdf.
2. Song F, Parekh S, Hooper L., Loke YK, Ryder J, Sutton AJ, et al Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess 2010;14:1-220.
3. Dwan K, Gamble C, Williamson P.R., Kirkham JJ, Reporting Bias Group. Systematic review of the empirical evidence of study publication bias and outcome reporting bias: an updated review. PLoS One 2013;8:e66844.
4. Wieseler B, Kerekes MF, Vervoelgyi V, McGauran N., Kaiser T. Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications. BMJ 2012;344:d8141.
5. Wieseler B, Wolfram N, McGauran N., Kerekes MF, Vervolgyi V, Kohlepp P, et al Completeness of reporting of patient-relevant clinical trial outcomes: comparison of unpublished clinical study reports with publicly available data. PLoS Med 2013;10:e1001526.
6. Doshi P, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open 2013;3:e002496.
7. European Medicines Agency. European public assessment reports: background and context. 2014. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general-content-000433.jsp&murl=&mid=.
8. Moher D, Hopewell S, Schulz K.F., Montori V., Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
9. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
10. United States Congress. Food and drug Administration Amendments Act of 2007: title VIII clinical trial databases; section 801 expanded clinical trial registry data bank. 27 Sep 2007. http://govtrack.us/congress/billtext.xpd?bill=h110-3580.
11. European Parliament, Council of the European Union. Regulation (Eu) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA relevance). Official J European Union 2014;57(L 158):1-76.
12. Vale CL, Tierney JF, Burdett S. Can trial quality be reliably assessed from published reports of cancer trials: evaluation of risk of bias assessments in systematic reviews. BMJ 2013;346:f1798.
13. Riveros C, Dechartres A, Perrodeau E., Haneef R, Boutron I, Ravaud P. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med 2013;10:e1001566; discussion e66.
14. Zarin DA, Tse T, Williams R.J., Califf RM, Ide NC The ClinicalTrials.gov results database: update and key issues. N Engl J Med 2011;364:852-60.
15. Nguyen TA, Dechartres A, Belgherbi S., Ravaud P. Public availability of results of trials assessing cancer drugs in the United States. J Clin Oncol 2013;31:2998-3003.
16. Barbui C, Baschirotto C, Cipriani A. EMA must improve the quality of its clinical trial reports. BMJ 2011;342:d2291.
17. Habibi R, Lexchin J. Quality and quantity of information in summary basis of decision documents issued by Health Canada. PLoS One 2014;9:e92038.
18. Schwartz LM, Woloshin S. Lost in transmission: FDA drug information that never reaches clinicians. N Engl J Med 2009;361:1717-20.
19. European Medicines Agency. Edurant: European public assessment report. 22 Nov 2011. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002264/WC500118872.pdf.
20. Bundesministerium für Gesundheit. Gesetz zur Neuordnung des Arzneimittelmarktes in der gesetzlichen Krankenversicherung (Arzneimittelmarktneuordnungsgesetz - AMNOG). Bundesgesetzblatt Teil 1 2010:2262-77.
21. Hörn H., Nink K, McGauran N., Wieseler B. Early benefit assessment of new drugs in Germany: results from 2011 to 2012. Health Policy 2014;116:147-53.
22. Kanavos P, Vandoros S, Irwin R., Nicod E, Casson M. Differences in costs and access to pharmaceutical products in the EU. 2011. www.europarl.europa.eu/document/activities/cont/201201/20120130ATT36575/20120130ATT36575EN.pdf.
23. Bundesministerium für Gesundheit. Verordnung über die Nutzenbewertung von Arzneimitteln nach § 35a Absatz 1 SGB V für Erstattungsvereinbarungen nach § 130b SGB V (Arzneimittel-Nutzenbewertungsverordnung - AM-NutzenV). Bundesgesetzblatt Teil 1 2010:2324-8.
24. Gemeinsamer Bundesausschuss. Verfahrensordnung des Gemeinsamen Bundesausschusses. 19 Nov 2014. www.g-ba.de/downloads/62-492-938/VerfO-2014-06-19-iK-2014-11-19.pdf.
25. Gemeinsamer Bundesausschuss. Anlage II zum 5. Kapitel: Format und Gliederung des Dossiers, einzureichende Unterlagen, Vorgaben für technische Standards. 2014. www.g-ba.de/informationen/richtlinien/anlage/167/.
26. Institute for Quality and Efficiency in Health Care. General methods: version 4.1. IQWiG, 2013. www.iqwig.de/download/IQWiG-General-Methods-Version-%204-1.pdf.
27. Janssen. Incivo 375 mg Filmtabletten: Fachinformation. Dec 2013. www.fachinfo.
28. Waffenschmidt S, Janzen T, Hausner E., Kaiser T. Simple search techniques in PubMed are potentially suitable for evaluating the completeness of systematic reviews. J Clin Epidemiol 2013;66:660-5.
29. Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions. Wiley, 2008. http://handbook.cochrane.org/.
30. Berntgen M, Gourvil A, Pavlovic M., Goetsch W, Eichler HG, Kristensen F. Improving the contribution of regulatory assessment reports to health technology assessments: a collaboration between the European Medicines Agency and the European Network for Health Technology Assessments. Value Health 2014;17:634-41.
31. European Medicines Agency. Guidance document on the content of the rapporteur day 80 critical assessment report: overview and list of questions. 2014. www.ema.europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2009/10/WC500004800.pdf.
32. European Medicines Agency. Publication of clinical reports: EMA adopts landmark policy to take effect on 1 January 2015. 2 Oct 2014. www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2014/10/news-detail-002181.jsp&mid=WC0b01ac058004d5c1.
33. All Trials. EMA removes some restrictions from its data sharing policy. 2 Oct 2014. www.alltrials.net/news/ema-removes-some-restrictions-from-its-data-sharing-policy/.
34. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008;5:e217.
35. Turner EH, Matthews AM, Linardatos E, Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008;358:252-60.
36. To MJ, Jones J, Emara M., Jadad AR Are reports of randomized controlled trials improving over time? A systematic review of 284 articles published in high-impact general and specialized medical journals. PLoS One 2013;8:e84779.
37. Haidich AB, Birtsou C, Dardavessis T., Tirodimos I, Arvanitidou M. The quality of safety reporting in trials is still suboptimal: survey of major general medical journals. J Clin Epidemiol 2011;64:124-35.
38. Prayle AP, Hurley MN, Smyth AR Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ 2012;344:d7373.
39. Tse T, Williams RJ, Zarin DA Reporting "basic results" in ClinicalTrials.gov. Chest 2009;136:295-303.
40. Gill CJ. How often do US-based human subjects research studies register on time, and how often do they post their results? A statistical analysis of the Clinicaltrials.gov database. BMJ Open 2012;2:e001186.
41. European Medicines Agency. Brilique: European public assessment report. 2011. www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/001241/WC500100492.pdf.
42. Wise J. NICE recommends wider use of statins in draft guidelines. BMJ 2014;348:g1518.
43. Goldacre B. Meta-analysis of side effects of statins shows need for trial transparency. BMJ 2014;348:g2940.
44. Basch E. Toward patient-centered drug development in oncology. N Engl J Med 2013;369:397-400.
45. European Medicines Agency. European public assessment reports. 2014. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar-search.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125&jsenabled=true.
46. Food and Drug Administration. New molecular entity approvals for 2011. 14 Nov 2013. www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm285554.htm.
47. Food and Drug Administration. New molecular entity approvals for 2012. 15 Jan 2014. www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm336115.htm.